COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data
We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Reflecting on Innovation and Hope during Blood Cancer Awareness Month
Every September, the healthcare, life sciences, and patient advocacy communities mark Blood Cancer Awareness Month, a time to focus on raising awareness about leukemia, lymphoma, myeloma, and other cancers that affect the blood or bone marrow.
RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?
In this new blog series from COTA and Deloitte, we will explore the expanding role of real-world data in oncology.
Summer Interns Explore Career Pathways, Pick Up New Skills from COTA Mentors
COTA’s Summer Internship Program provides an opportunity for college students to explore their career interests, learn new skills, and receive mentorship from experts in the field. This year’s interns come from a variety of backgrounds and majors, and are working in a number of different areas within COTA.
Noel Alaka Joins COTA’s Life Science Team to Accelerate Adoption of Oncology Real-World Data
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
Meet Our Interns!
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
Leading COTA into the Next Chapter of Data-Driven Precision Oncology
I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences
COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition
Four abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.
